Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer

Background Single-agent pembrolizumab treatment of hormone receptor-positive metastatic breast cancer (MBC) has demonstrated modest clinical responses. Little is known about potential biomarkers or mechanisms of response to immune checkpoint inhibitors (ICIs) in patients with HR+ MBC. The present st...

Full description

Bibliographic Details
Main Authors: Yuan Yuan, Peter Lee, Colt Egelston, Weihua Guo, Susan Yost, Jin Sun Lee, David Rose, Christian Avalos, Paul Frankel, Daniel Schmolze, James Waisman
Format: Article
Language:English
Published: BMJ Publishing Group 2021-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/3/e002084.full

Internet

https://jitc.bmj.com/content/9/3/e002084.full

Similar Items